RxDoctor Payments Data

Walter Waugh, MD

Family Medicine · Edmond, OKNPI 1669531604

Payments from drug & device makers

$8,819in general payments, 2019–2025

Across 536 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$842
  • Otsuka America Pharmaceutical, Inc.$562
  • Takeda Pharmaceuticals U.S.A., Inc.$557
  • Bayer$520
  • Amgen$326
  • plus $4K from 54 others

What the payments were for

  • Speaking & faculty fees$290%
  • Food & beverage$8,778100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)116$1,769
Novo Nordisk65$842
Otsuka America Pharmaceutical, Inc.37$562
Takeda Pharmaceuticals U.S.A., Inc.30$557
Bayer25$520
Amgen(2 entities)19$326
Lilly USA, LLC18$300
IBSA Pharma Inc.17$280
Corcept Therapeutics10$220
Antares Pharma, Inc.11$209
Corium, LLC11$199
Boehringer Ingelheim8$152
Sunovion Pharmaceuticals Inc.8$149
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$146
GSK8$127
Arbor Pharmaceuticals, Inc.9$120
Therapeuticsmd, Inc.7$102
Kowa Pharmaceuticals America, Inc.6$98
Eisai Inc.6$95
Radius Health, Inc.5$91
Vertical Pharmaceuticals, LLC4$90
Adlon Therapeutics L.p.6$88
Abbott4$83
Currax Pharmaceuticals LLC6$79
Alfasigma USA, Inc.1$72
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$71
Teva Pharmaceuticals USA, Inc.5$70
Supernus Pharmaceuticals, Inc.4$70
Azurity Pharmaceuticals, Inc.4$59
Idorsia Pharmaceuticals US Inc3$56
Ironwood Pharmaceuticals, Inc3$55
Biohaven Pharmaceutical Holding Company Ltd.3$55
Mayne Pharma Commercial LLC3$52
Pfizer3$50
Dexcom, Inc.2$48
Amneal Pharmaceuticals LLC3$48
Johnson & Johnson3$47
Nalpropion Pharmaceuticals LLC3$44
Biohaven Pharmaceuticals, Inc.2$42
Lundbeck LLC2$42
Merck3$42
Shire North American Group Inc2$38
Zimmer Biomet2$37
Clarus Therapeutics Inc.2$36
Tris Pharma Inc2$35
Ironshore Pharmaceuticals Inc.2$34
Jazz Pharmaceuticals Inc.2$33
Nestle Healthcare Nutrition Inc.2$33
Esperion Therapeutics, Inc.2$32
Medicure Pharma Inc.1$29
Upsher-smith Laboratories LLC1$25
Insulet Corporation1$25
AstraZeneca2$25
Axsome Therapeutics, Inc.1$22
Almatica Pharma LLC1$22
ANI Pharmaceuticals, Inc.1$22
Pacira Pharmaceuticals Incorporated1$21
Mission Pharmacal Company1$19
Scynexis, Inc.1$19
Ascend Therapeutics US, LLC1$19

How this compares

$8,819 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$102,067
Medicare patients
277
Services billed
4,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide123$146,655
OzempicSemaglutide128$145,274
OfevNintedanib Esylate11$137,243
JardianceEmpagliflozin67$68,106
TrulicityDulaglutide62$62,193
FarxigaDapagliflozin Propanediol72$61,522
Tresiba Flextouch U-200Insulin Degludec35$41,536
TymlosAbaloparatide12$37,164
JanuviaSitagliptin Phosphate41$34,459
VascepaIcosapent Ethyl28$18,513
Humalog Kwikpen U-200Insulin Lispro13$16,950
XyostedTestosterone Enanthate27$15,326
JanumetSitagliptin Phos/Metformin Hcl11$11,046
SynthroidLevothyroxine Sodium110$10,565
Tresiba Flextouch U-100Insulin Degludec11$10,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$300$210,676199 claims
Boehringer IngelheimOfev, Jardiance$152$205,34978 claims
Novo NordiskOzempic$842$145,274128 claims
AstraZenecaFarxiga$25$61,52272 claims
MerckJanuvia, Janumet$42$45,50552 claims
Radius Health, Inc.Tymlos$91$37,16412 claims
Antares Pharma, Inc.Xyosted$209$15,32627 claims
AbbVieSynthroid, Armour Thyroid$1,769$11,621121 claims
GSKBreo Ellipta$127$10,11414 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$48$2,770195 claims
Arbor Pharmaceuticals, Inc.Edarbi$120$2,48311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →